

# Hans M G Princen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5844382/publications.pdf>

Version: 2024-02-01

114  
papers

5,519  
citations

87723

38  
h-index

85405

71  
g-index

119  
all docs

119  
docs citations

119  
times ranked

7054  
citing authors

#	ARTICLE	IF	CITATIONS
1	No effects of PCSK9-inhibitor treatment on spatial learning, locomotor activity, and novel object recognition in mice. <i>Behavioural Brain Research</i> , 2021, 396, 112875.	1.2	3
2	Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men. <i>Scientific Reports</i> , 2021, 11, 5050.	1.6	10
3	Systemic PFOS and PFOA exposure and disturbed lipid homeostasis in humans: what do we know and what not?. <i>Critical Reviews in Toxicology</i> , 2021, 51, 141-164.	1.9	78
4	Common Variants Associated With OSMR Expression Contribute to Carotid Plaque Vulnerability, but Not to Cardiovascular Disease in Humans. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 658915.	1.1	3
5	Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 161, 105776.	1.9	7
6	Chronic Oral Administration of Mineral Oil Compared With Corn Oil: Effects on Gut Permeability and Plasma Inflammatory and Lipid Biomarkers. <i>Frontiers in Pharmacology</i> , 2021, 12, 681455.	1.6	2
7	Novel high-intensive cholesterol-lowering therapies do not ameliorate knee OA development in humanized dyslipidemic mice. <i>Osteoarthritis and Cartilage</i> , 2021, 29, 1314-1323.	0.6	6
8	Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice. <i>Journal of Lipid Research</i> , 2020, 61, 365-375.	2.0	48
9	In Vivo Magnetic Resonance Imaging-Based Detection of Heterogeneous Endothelial Response in Thoracic and Abdominal Aorta to Short-Term High-Fat Diet Ascribed to Differences in Perivascular Adipose Tissue in Mice. <i>Journal of the American Heart Association</i> , 2020, 9, e016929.	1.6	24
10	Effects of Inhibition or Deletion of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) on Intracerebral Hemorrhage Volumes in Mice. <i>Stroke</i> , 2020, 51, e297-e298.	1.0	2
11	Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative. <i>Liver International</i> , 2020, 40, 2860-2876.	1.9	12
12	Inhibition of macrophage proliferation dominates plaque regression in response to cholesterol lowering. <i>Basic Research in Cardiology</i> , 2020, 115, 78.	2.5	37
13	Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice. <i>Hepatology Communications</i> , 2020, 4, 193-207.	2.0	15
14	Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice. <i>Scientific Reports</i> , 2019, 9, 11079.	1.6	29
15	Triple Treatment With Alirocumab And Evinacumab On Top Of Atorvastatin Regresses Lesion Size And Improves Plaque Phenotype In Apoe*3leiden.Cetp Mice. <i>Atherosclerosis</i> , 2019, 287, e12.	0.4	1
16	Oncostatin M reduces atherosclerosis development in APOE*3Leiden.CETP mice and is associated with increased survival probability in humans. <i>PLoS ONE</i> , 2019, 14, e0221477.	1.1	10
17	The Structurally Engineered Fatty Acid Icosabutate Improves Lipid Metabolism And Reduces Severity Of Atherogenesis In Mice. <i>Atherosclerosis</i> , 2019, 287, e55.	0.4	0
18	Dose Effects of Ammonium Perfluorooctanoate on Lipoprotein Metabolism in APOE*3-Leiden.CETP Mice. <i>Toxicological Sciences</i> , 2019, 168, 519-534.	1.4	20

#	ARTICLE	IF	CITATIONS
19	The APOE<math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:msup><mml:mrow /><mml:mrow><mml:mo>^</mml:mo></mml:mrow></mml:msup></mml:math>3-Leiden Heterozygous Glucokinase Knockout Mouse as Novel Translational Disease Model for Type 2 Diabetes, Dyslipidemia, and Diabetic Atherosclerosis. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-13.	1.0	8
20	FRI0528&...HIGH INTENSIVE THERAPEUTIC LOWERING OF SYSTEMIC CHOLESTEROL DOES NOT AMELIORATE OA DEVELOPMENT IN KNEE JOINTS OF HUMANIZED DYSLIPIDEMIC MICE. , 2019, , .		1
21	Results, meta-analysis and a first evaluation of UNOxR, the urinary nitrate-to-nitrite molar ratio, as a measure of nitrite reabsorption in experimental and clinical settings. <i>Amino Acids</i> , 2018, 50, 799-821.	1.2	23
22	Variable cartilage degradation in mice with diet-induced metabolic dysfunction: food for thought. <i>Osteoarthritis and Cartilage</i> , 2018, 26, 95-107.	0.6	23
23	Inflammatory cytokine oncostatin M induces endothelial activation in macro- and microvascular endothelial cells and in APOE*3Leiden.CETP mice. <i>PLoS ONE</i> , 2018, 13, e0204911.	1.1	15
24	Inflammatory Cytokine Oncostatin M Induces Endothelial Activation in vitro and in APOE*3Leiden.CETP Mice. <i>Atherosclerosis Supplements</i> , 2018, 32, 19.	1.2	1
25	The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 55.	1.1	47
26	Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase. <i>Atherosclerosis</i> , 2017, 257, 186-194.	0.4	17
27	The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. <i>European Heart Journal</i> , 2017, 38, 2499-2507.	1.0	176
28	Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 211-221.	13.9	633
29	Cardiovascular safety of BCR-ABL1 tyrosine kinase inhibitors: imatinib and ponatinib decrease plasma cholesterol and atherosclerosis in APOE3*Leiden.CETP Mice. <i>Atherosclerosis</i> , 2017, 263, e29-e30.	0.4	0
30	Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis. <i>Atherosclerosis</i> , 2017, 267, 116-126.	0.4	23
31	Affitope-based anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) vaccine (AT04A) reduces atherosclerosis in APOE*3Leiden.CETP mice. <i>Atherosclerosis</i> , 2016, 252, e253-e254.	0.4	0
32	The APOE*3Leiden.GK +/- mouse as novel translational model for dyslipidemia, type 2 diabetes and macrovascular complications. <i>Atherosclerosis</i> , 2016, 252, e226-e227.	0.4	1
33	Comment on "Hypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of mice" by Rebholz S.L. et al. <i>Toxicol. Rep.</i> 2016 (3) 46-54. <i>Toxicology Reports</i> , 2016, 3, 306-309.	1.6	11
34	Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes. <i>British Journal of Pharmacology</i> , 2015, 172, 5293-5305.	2.7	29
35	Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising A systematic review and meta-analysis of relevant preclinical studies and clinical trials. <i>European Journal of Pharmacology</i> , 2015, 763, 48-63.	1.7	44
36	No effects of atorvastatin (10mg/d or 80mg/d) on nitric oxide, prostacyclin, thromboxane and oxidative stress in type 2 diabetes mellitus patients of the DALI study. <i>Pharmacological Research</i> , 2015, 94, 1-8.	3.1	11

#	ARTICLE	IF	CITATIONS
37	Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. <i>European Heart Journal</i> , 2015, 36, 39-50.	1.0	65
38	Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. <i>Journal of Lipid Research</i> , 2015, 56, 2085-2093.	2.0	27
39	Metformin Lowers Plasma Triglycerides by Promoting VLDL-Triglyceride Clearance by Brown Adipose Tissue in Mice. <i>Diabetes</i> , 2014, 63, 880-891.	0.3	129
40	<scp>APOE</scp>*3Leiden</scp>. <scp>CETP</scp> transgenic mice as model for pharmaceutical treatment of the metabolic syndrome. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 537-544.	2.2	42
41	PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. <i>Journal of Lipid Research</i> , 2014, 55, 2370-2379.	2.0	59
42	Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. <i>Journal of Lipid Research</i> , 2014, 55, 2103-2112.	2.0	165
43	Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice—a translational model for atherosclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 921-927.	0.5	67
44	Alirocumab, monoclonal antibody to PCSK9, dose-dependently decreases atherosclerosis, improves plaque stability and shows additive effects with atorvastatin in apoe*3leiden.cetp mice. <i>Atherosclerosis</i> , 2014, 235, e19.	0.4	1
45	Osteoarthritis development is induced by increased dietary cholesterol in APOE*3Leiden.CETP mice, a translational model for atherosclerosis, and can be inhibited by atorvastatin. <i>Osteoarthritis and Cartilage</i> , 2013, 21, S65-S66.	0.6	5
46	Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice. <i>Journal of Nutritional Biochemistry</i> , 2013, 24, 1423-1430.	1.9	49
47	Colestilan decreases weight gain by enhanced NEFA incorporation in biliary lipids and fecal lipid excretion. <i>Journal of Lipid Research</i> , 2013, 54, 1255-1264.	2.0	15
48	Both Transient and Continuous Corticosterone Excess Inhibit Atherosclerotic Plaque Formation in APOE*3-Leiden.CETP Mice. <i>PLoS ONE</i> , 2013, 8, e63882.	1.1	14
49	Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol. <i>PLoS ONE</i> , 2013, 8, e66467.	1.1	36
50	Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin. <i>Journal of Hypertension</i> , 2012, 30, 107-116.	0.3	27
51	Distribution of perfluorooctanesulfonate and perfluorooctanoate into human plasma lipoprotein fractions. <i>Toxicology Letters</i> , 2012, 210, 360-365.	0.4	32
52	Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice. <i>Biochemical Pharmacology</i> , 2012, 84, 821-829.	2.0	21
53	172 NIACIN, ATORVASTATIN AND FENOFIBRATE DECREASE PLASMA CETP BY REDUCTION OF THE HEPATIC MACROPHAGE CONTENT IN APOE*3-LEIDEN.CETP MICE. <i>Atherosclerosis Supplements</i> , 2011, 12, 38.	1.2	0
54	Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels. <i>British Journal of Pharmacology</i> , 2011, 162, 1553-1563.	2.7	32

#	ARTICLE	IF	CITATIONS
55	Perfluoroalkyl Sulfonates Cause Alkyl Chain Length-Dependent Hepatic Steatosis and Hypolipidemia Mainly by Impairing Lipoprotein Production in APOE*3-Leiden CETP Mice. <i>Toxicological Sciences</i> , 2011, 123, 290-303.	1.4	118
56	CETP does not affect triglyceride production or clearance in APOE*3-Leiden mice. <i>Journal of Lipid Research</i> , 2010, 51, 97-102.	2.0	7
57	Fenofibrate Increases Very Low Density Lipoprotein Triglyceride Production Despite Reducing Plasma Triglyceride Levels in APOE*3-Leiden.CETP Mice. <i>Journal of Biological Chemistry</i> , 2010, 285, 25168-25175.	1.6	28
58	P28 RESVERATROL PROTECTS AGAINST ATHEROSCLEROSIS DEVELOPMENT IN APOE*3-LEIDEN.CETP MICE. <i>Atherosclerosis Supplements</i> , 2010, 11, 22.	1.2	0
59	P70 THE EFFECT OF ALISKIREN ON ATHEROSCLEROSIS DEVELOPMENT IN APOE*3LEIDEN.CETP TRANSGENIC MICE WITH AND WITHOUT TREATMENT WITH ATORVASTATIN. <i>Atherosclerosis Supplements</i> , 2010, 11, 31.	1.2	0
60	P328 APOE*3LEIDEN.CETP TRANSGENIC MICE AS MODEL FOR THE METABOLIC SYNDROME. <i>Atherosclerosis Supplements</i> , 2010, 11, 86.	1.2	0
61	Bexarotene Induces Dyslipidemia by Increased Very Low-Density Lipoprotein Production and Cholesteryl Ester Transfer Protein-Mediated Reduction of High-Density Lipoprotein. <i>Endocrinology</i> , 2009, 150, 2368-2375.	1.4	49
62	The dual PPAR $\alpha/\gamma$ agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice. <i>British Journal of Pharmacology</i> , 2009, 156, 1067-1075.	2.7	34
63	PXR agonism decreases plasma HDL levels in ApoE $\alpha\beta$ 3-Leiden.CETP mice. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2009, 1791, 191-197.	1.2	33
64	Preferential campesterol incorporation into various tissues in apolipoprotein E*3-Leiden mice consuming plant sterols or stanols. <i>Metabolism: Clinical and Experimental</i> , 2008, 57, 1241-1247.	1.5	13
65	Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 2016-2022.	1.1	161
66	The impact of metabolic syndrome and CRP on vascular phenotype in type 2 diabetes mellitus. <i>European Journal of Internal Medicine</i> , 2008, 19, 115-121.	1.0	13
67	DUAL PPAR-ALPHA/GAMMA AGONIST TESAGLITAZAR BLOCKS PROGRESSION OF PRE-EXISTING ATHEROSCLEROSIS IN APOE*3LEIDEN.CETP TRANSGENIC MICE. <i>Atherosclerosis Supplements</i> , 2008, 9, 209.	1.2	0
68	Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. <i>Atherosclerosis</i> , 2008, 197, 57-63.	0.4	76
69	Torcetrapib Does Not Reduce Atherosclerosis Beyond Atorvastatin and Induces More Proinflammatory Lesions Than Atorvastatin. <i>Circulation</i> , 2008, 117, 2515-2522.	1.6	89
70	Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE*3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban)*. <i>Critical Care Medicine</i> , 2008, 36, 2576-2582.	0.4	35
71	The Cholesterol-Raising Factor from Coffee Beans, Cafestol, as an Agonist Ligand for the Farnesoid and Pregnane X Receptors. <i>Molecular Endocrinology</i> , 2007, 21, 1603-1616.	3.7	107
72	Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. <i>Journal of Lipid Research</i> , 2007, 48, 1763-1771.	2.0	86

#	ARTICLE	IF	CITATIONS
73	Mouse Models for Atherosclerosis and Pharmaceutical Modifiers. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 1706-1721.	1.1	470
74	Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice. <i>Journal of Hypertension</i> , 2007, 25, 2454-2462.	0.3	27
75	Plasma annexin A5 level relates inversely to the severity of coronary stenosis. <i>Biochemical and Biophysical Research Communications</i> , 2007, 356, 674-680.	1.0	17
76	Anti-Atherosclerotic Effect of Amlodipine, Alone and in Combination With Atorvastatin, in APOE*3-Leiden/hCRP Transgenic Mice. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, 89-95.	0.8	21
77	Cholesterol 7Î±-Hydroxylase Deficiency in Mice on an APOE*3-Leiden Background Increases Hepatic ABCA1 mRNA Expression and HDL-Cholesterol. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 2724-2730.	1.1	8
78	Genetic variation in the rate-limiting enzyme in cholesterol catabolism (cholesterol 7Î±-hydroxylase) influences the progression of atherosclerosis and risk of new clinical events. <i>Clinical Science</i> , 2005, 108, 539-545.	1.8	32
79	Effect of Low Dose Atorvastatin Versus Diet-Induced Cholesterol Lowering on Atherosclerotic Lesion Progression and Inflammation in Apolipoprotein E*3â€œLeiden Transgenic Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 161-167.	1.1	77
80	Rosuvastatin Reduces Plasma Lipids by Inhibiting VLDL Production and Enhancing Hepatobiliary Lipid Excretion in ApoE*3-Leiden Mice. <i>Journal of Cardiovascular Pharmacology</i> , 2005, 45, 53-60.	0.8	21
81	CYP7A1 A-278C Polymorphism Affects the Response of Plasma Lipids after Dietary Cholesterol or Cafestol Interventions in Humans. <i>Journal of Nutrition</i> , 2004, 134, 2200-2204.	1.3	36
82	Well-Characterized Garlic-Derived Materials Are Not Hypolipidemic in APOE*3-Leiden Transgenic Mice. <i>Journal of Nutrition</i> , 2004, 134, 1500-1503.	1.3	6
83	Cholesterol 7Î±-Hydroxylase Deficiency in Mice on an APOE*3-Leiden Background Impairs Very-Low-Density Lipoprotein Production. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 768-774.	1.1	24
84	Serum carotenoids and vitamins in relation to markers of endothelial. <i>European Journal of Epidemiology</i> , 2004, 19, 915-921.	2.5	112
85	Î±-Tocopherol levels in plasma in new-onset, insulin-dependent diabetes mellitus. <i>European Journal of Internal Medicine</i> , 2004, 15, 371-374.	1.0	4
86	Absence of an atheroprotective effect of the garlic powder printanor in APOE*3-Leiden transgenic mice. <i>Atherosclerosis</i> , 2004, 177, 291-297.	0.4	13
87	Evidence for anti-inflammatory activity of statins and PPARÎ± activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. <i>Blood</i> , 2004, 103, 4188-4194.	0.6	166
88	Hepatic low-density lipoprotein receptorâ€œrelated protein deficiency in mice increases atherosclerosis independent of plasma cholesterol. <i>Blood</i> , 2004, 103, 3777-3782.	0.6	35
89	Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2003, 35, 109-118.	0.9	26
90	Increased Fecal Bile Acid Excretion in Transgenic Mice With Elevated Expression of Human Phospholipid Transfer Protein. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 892-897.	1.1	56

#	ARTICLE	IF	CITATIONS
91	Rosuvastatin Reduces Atherosclerosis Development Beyond and Independent of Its Plasma Cholesterol-Lowering Effect in APOE*3-Leiden Transgenic Mice. <i>Circulation</i> , 2003, 108, 1368-1374.	1.6	157
92	Differential Effects of Amlodipine and Atorvastatin Treatment and Their Combination on Atherosclerosis in ApoE*3-Leiden Transgenic Mice. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 42, 63-70.	0.8	44
93	Vitamin E inhibits lipid peroxidation-induced adhesion molecule expression in endothelial cells and decreases soluble cell adhesion molecules in healthy subjects. <i>Cardiovascular Research</i> , 2003, 57, 563-571.	1.8	49
94	Fibrates down-regulate IL-1 $\alpha$ -stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NF $\kappa$ B/C/EBP $\beta$ complex formation. <i>Blood</i> , 2003, 101, 545-551.	0.6	211
95	Genetic Analysis of Indicators of Cholesterol Synthesis and Absorption: Lathosterol and Phytosterols in Dutch Twins and Their Parents. <i>Twin Research and Human Genetics</i> , 2003, 6, 307-314.	1.5	17
96	Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice. <i>Atherosclerosis</i> , 2002, 164, 65-71.	0.4	34
97	Design of a Targeted Peptide Nucleic Acid Prodrug To Inhibit Hepatic Human Microsomal Triglyceride Transfer Protein Expression in Hepatocytes. <i>Bioconjugate Chemistry</i> , 2002, 13, 295-302.	1.8	33
98	Increased lipogenesis and resistance of lipoproteins to oxidative modification in two patients with glycogen storage disease type 1a. <i>Journal of Pediatrics</i> , 2002, 140, 256-260.	0.9	40
99	HOE 402 lowers serum cholesterol levels by reducing VLDL-lipid production, and not by induction of the LDL receptor, and reduces atherosclerosis in wild-type and LDL receptor-deficient mice. <i>Biochemical Pharmacology</i> , 2002, 63, 1755-1761.	2.0	4
100	Dietary Plant Stanol Esters Reduce VLDL Cholesterol Secretion and Bile Saturation in Apolipoprotein E*3-Leiden Transgenic Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 1046-1052.	1.1	49
101	Acyl-CoA:Cholesterol Acyltransferase Inhibitor Avasimibe Reduces Atherosclerosis in Addition to Its Cholesterol-Lowering Effect in ApoE*3-Leiden Mice. <i>Circulation</i> , 2001, 103, 1778-1786.	1.6	115
102	Cafestol Increases Serum Cholesterol Levels in Apolipoprotein E*3-Leiden Transgenic Mice by Suppression of Bile Acid Synthesis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 1551-1556.	1.1	42
103	Normal Oxidative Stress and Enhanced Lipoprotein Resistance to In Vitro Oxidation in Hypertriglyceridemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 2434-2440.	1.1	14
104	Acyl-coenzyme A: Cholesterol acyltransferase inhibitor, avasimibe, stimulates bile acid synthesis and cholesterol 7 $\alpha$ -hydroxylase in cultured rat hepatocytes and in vivo in the rat. <i>Hepatology</i> , 1999, 30, 491-500.	3.6	47
105	LDL Oxidation and Extent of Coronary Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 193-199.	1.1	39
106	No Effect of Consumption of Green and Black Tea on Plasma Lipid and Antioxidant Levels and on LDL Oxidation in Smokers. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 833-841.	1.1	165
107	Cafestol, the Cholesterol-Raising Factor in Boiled Coffee, Suppresses Bile Acid Synthesis by Downregulation of Cholesterol 7 $\alpha$ -Hydroxylase and Sterol 27-Hydroxylase in Rat Hepatocytes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 3064-3070.	1.1	57
108	Structural Aspects of Bile Acids Involved in the Regulation of Cholesterol 7 $\alpha$ -Hydroxylase and Sterol 27-Hydroxylase. <i>FEBS Journal</i> , 1995, 228, 596-604.	0.2	19

#	ARTICLE	IF	CITATIONS
109	Insulin suppresses bile acid synthesis in cultured rat hepatocytes by down-regulation of cholesterol 7 $\alpha$ -hydroxylase and sterol 27-hydroxylase gene transcription. <i>Hepatology</i> , 1995, 21, 501-510.	3.6	88
110	Antioxidants and Coronary Heart Disease. <i>Annals of Medicine</i> , 1994, 26, 429-434.	1.5	56
111	Bile acids exert negative feedback control on bile acid synthesis in cultured pig hepatocytes by suppression of cholesterol 7 $\alpha$ -hydroxylase activity. <i>Hepatology</i> , 1990, 12, 1209-1215.	3.6	23
112	Inhibition and induction of bile acid synthesis by ketoconazole effects on bile formation in the rat. <i>Lipids</i> , 1989, 24, 759-764.	0.7	12
113	Regulation of low density lipoprotein receptor activity in primary cultures of human hepatocytes by serum lipoproteins. <i>Hepatology</i> , 1986, 6, 1356-1360.	3.6	39
114	Free cytoplasmic messenger ribonucleoprotein complexes from rabbit reticulocytes. <i>Molecular Biology Reports</i> , 1979, 5, 59-64.	1.0	9